Product image of Kivexa (Abacavir Sulfate, Lamivudine) supplied by GNH India

Kivexa

Active Ingredient:
Abacavir Sulfate, Lamivudine
Origin:
EU

Kivexa (Abacavir Sulfate, Lamivudine)

Abacavir Sulfate and Lamivudine, the active ingredients in Kivexa, are nucleoside reverse transcriptase inhibitors (NRTIs) presented as oral tablets. They are used in combination therapy to suppress HIV-1 replication in adults and adolescents living with HIV infection. The fixed‑dose combination simplifies treatment regimens and improves adherence for patients.

GNH India supplies Kivexa as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and providing the product to hospitals, pharmacies, and clinics worldwide through validated cold‑chain logistics and regulatory support.

Manufacturer / TM Owner

Viiv Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Kivexa, a nucleoside reverse transcriptase inhibitor, is used in antiretroviral therapy for HIV-1 infection.
  • HIV-1 infection (adults): reduces viral load and increases CD4+ cell counts when used as part of combination antiretroviral therapy.
  • HIV-1 infection (adolescents): provides effective viral suppression as part of a regimen approved for patients aged 12 years and older.
  • Co‑infection with hepatitis B: lamivudine component offers activity against HBV, supporting liver health while treating HIV.

How It Works

  • Abacavir and lamivudine are nucleoside analogues that require intracellular phosphorylation to their active triphosphate forms. These active metabolites compete with natural nucleotides for incorporation into the viral DNA chain by HIV reverse transcriptase, causing premature chain termination and thereby inhibiting viral replication.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Headache: transient cranial discomfort.
  • Fatigue: general tiredness.
  • Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects

  • Hypersensitivity reaction: potentially life‑threatening, especially with abacavir in HLA‑B*57:01 carriers.
  • Severe liver injury: elevated transaminases, jaundice.
  • Lactic acidosis: metabolic disturbance requiring urgent care.
  • Stevens‑Johnson syndrome: severe skin and mucosal reaction.

Precautions & Warnings

  • Before initiating therapy, consider the following precautions.
  • Screen for HLA‑B*57:01 before starting abacavir: avoid in positive patients.
  • Monitor liver function tests regularly: detect hepatotoxicity early.
  • Assess renal function: dose adjustment may be needed in severe impairment.
  • Educate patients about hypersensitivity signs: stop drug immediately if they occur.
  • Pregnancy and breastfeeding: use only if benefit outweighs risk; limited data available.
  • Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture and light.

Avoid Interactions

Kivexa may interact with several medicines; monitor accordingly.

Major Interactions (Avoid)

  • Concurrent use with didanosine: increased risk of pancreatitis.
  • Co‑administration with ribavirin: may increase hemolytic anemia.
  • Use with other NRTIs that cause mitochondrial toxicity: avoid combined toxicity.
  • Strong CYP3A4 inducers (e.g., rifampicin) may reduce lamivudine levels.

Moderate Interactions (Monitor Closely)

  • Protease inhibitors (e.g., lopinavir/ritonavir) may increase abacavir levels; monitor.
  • Nephrotoxic agents (e.g., tenofovir) require renal monitoring when combined.

Frequently Asked Questions

Kivexa is a fixed‑dose combination of abacavir sulfate and lamivudine used as part of antiretroviral therapy to treat HIV‑1 infection in adults and adolescents. It helps suppress viral replication and supports immune recovery when prescribed alongside other antiretroviral agents.

Abacavir sulfate is a guanosine nucleoside analogue. After intracellular phosphorylation to its active triphosphate, it competes with natural deoxyguanosine triphosphate for incorporation into viral DNA by reverse transcriptase, causing premature chain termination and blocking HIV replication.

The specific dose of Kivexa is determined by the prescribing clinician based on the patient’s age, weight, renal function, and overall treatment regimen. Dosage decisions follow national HIV treatment guidelines and should be individualized for each patient.

Safety data for Kivexa in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Kivexa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kivexa combines two NRTIs in a single tablet, simplifying dosing compared with separate agents. Compared with other fixed‑dose combinations, it offers a well‑studied safety profile and is particularly useful for patients who require both abacavir and lamivudine, though alternative regimens may be preferred based on resistance patterns or tolerability.

Kivexa tablets should be stored at ambient temperature below 25 °C. Keep them in the original packaging, protect from moisture and light, and ensure they are out of reach of children.

Kivexa is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with water and not crushed or chewed unless specifically advised.

The most serious risks include a hypersensitivity reaction, especially in patients with the HLA‑B*57:01 allele, severe liver injury, lactic acidosis, and rare skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these symptoms appear.

Kivexa should not be used in patients known to be positive for the HLA‑B*57:01 allele due to the risk of hypersensitivity. It is also contraindicated in individuals with severe hepatic impairment or those who have previously experienced a severe reaction to either component.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Abacavir Sulfate, Lamivudine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT